Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03437772
Other study ID # PHRC-N/2016/JLC-01
Secondary ID
Status Completed
Phase
First received
Last updated
Start date February 19, 2018
Est. completion date November 23, 2022

Study information

Verified date January 2023
Source Centre Hospitalier Universitaire de Nimes
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The investigators hypothesize that the mindfulness Cognitive Behavioral Therapy program will lead to a reduction in attention deficit and hyperactivity disorder symptoms, anxiety and depression, and improve self-confidence, emotional control, social integration and school results.


Recruitment information / eligibility

Status Completed
Enrollment 248
Est. completion date November 23, 2022
Est. primary completion date November 23, 2022
Accepts healthy volunteers No
Gender All
Age group 7 Years to 15 Years
Eligibility Inclusion Criteria: - If deemed able, the patient must have given his/her informed and signed consent - The parents (or legal guardian) of minor patients must have given their informed and signed consent. - The patient and participating parents must be insured or beneficiary of a health insurance plan - The patient is equal to or greater than 7 years old and less than or equal to 15 years old - The patient presents with attention deficit and hyperactivity disorder with an ADHDRS-PI score > 27 - The patient is currently not under treatment - OR - is treated with methylphenidate with a stable posology (not expected to vary in the near future) but remains symptomatic Exclusion Criteria: - The patient is participating in, or has participated in over the past three months, another trial or another study that may interfere with the results or conclusion of the present study - The patient is in an exclusion period determined by a previous study - The participating parent(s) is(are) under judicial protection, or is an adult under guardianship - It is impossible to correctly inform the patient or his/her parent or legal guardian - Patients or parents refusing participation, signature of the signed consent or follow-up procedures - Previously documented mental retardation (IQ < 70) or suspicion thereof by the investigator - The patient has already participated in cognitive behavioural therapy (individual or group) in the six months preceding inclusion - Patients diagnosed with autism spectrum disorder, psychotic disorder or bipolar disorder - The family has participated in a parental guidance programme in the last 6 months. - The family has already participated in the present study

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Mindfulness Cognitive Behavioral Therapy program
16 simultaneous-but-separate therapy sessions for parents and children.

Locations

Country Name City State
France CHU Montpellier Montpellier
France CHU Nimes Nîmes
France APHP - Hôpital Robert Debré Paris
France Chu de Strasbourg Strasbourg

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Nimes

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary ADHD symptom severity clinical-rated ADHD rating scale (ADHDRS-PI) questionnaire; score ranges 0-54 baseline
Primary ADHD symptom severity clinical-rated ADHD rating scale (ADHDRS-PI) questionnaire; score ranges 0-54 Month 5
Primary ADHD symptom severity clinical-rated ADHD rating scale (ADHDRS-PI) questionnaire; score ranges 0-54 Month 8
Secondary Parenting styles Parental Authority Questionnaire (PAQ); 30 items per parent Baseline
Secondary Parenting styles Parental Authority Questionnaire (PAQ); 30 items per parent Month 5
Secondary Parenting styles Parental Authority Questionnaire (PAQ); 30 items per parent Month 8
Secondary The quality of life for parents. Parental - Developmental Disorders - Quality of Life (PAR-DD-QoL) questionnaire; score ranges from 17-85 Baseline
Secondary The quality of life for parents. Parental - Developmental Disorders - Quality of Life (PAR-DD-QoL) questionnaire; score ranges from 17-85 Month 5
Secondary The quality of life for parents. Parental - Developmental Disorders - Quality of Life (PAR-DD-QoL) questionnaire; score ranges from 17-85 Month 8
Secondary Global function Clinical Global Impression Scale (CGI-S) questionnaire; score from 1-7 Baseline
Secondary Global function Clinical Global Impression Scale (CGI-S) questionnaire; score from 1-7 Month 5
Secondary Global function Clinical Global Impression Scale (CGI-S) questionnaire; score from 1-7 Month 8
Secondary Global function Children's Global Assessment Scale CGAS) questionnaire; score ranges from 0-100 Baseline
Secondary Global function Children's Global Assessment Scale CGAS) questionnaire; score ranges from 0-100 Month 5
Secondary Global function Children's Global Assessment Scale CGAS) questionnaire; score ranges from 0-100 Month 8
Secondary Social well-being and school parameters for children CONNERS for school teachers; cut-off for significant behavioral problem >15 his questionnaire will be given to the first patients included to 149 th patient included Baseline
Secondary Social well-being and school parameters for children SDQ ; cut-off for significant behavioral problem >15 . his questionnaire will be given to the first patients included to 149 th patient included his questionnaire will be given to 150th patients included to 248th patient included Baseline
Secondary Social well-being and school parameters for children SDQ ; cut-off for significant behavioral problem >15 . his questionnaire will be given to the first patients included to 149 th patient included his questionnaire will be given to 150th patients included to 248th patient included Month 5
Secondary Social well-being and school parameters for children CONNERS for school teachers; cut-off for significant behavioral problem >15 his questionnaire will be given to the first patients included to 149 th patient included Month 8
Secondary Anxiety in children Multidimensional Anxiety Scale for Children (MASC) questionnaire; 39-item, 4-point Likert scale Baseline
Secondary Anxiety in children Multidimensional Anxiety Scale for Children (MASC) questionnaire; 39-item, 4-point Likert scale Month 5
Secondary Anxiety in children Multidimensional Anxiety Scale for Children (MASC) questionnaire; 39-item, 4-point Likert scale Month 8
Secondary Depression in children Children depression inventory (CDI) questionnaire; score ranges from 0-54 Baseline
Secondary Depression in children Children depression inventory (CDI) questionnaire; score ranges from 0-54 Month 5
Secondary Depression in children Children depression inventory (CDI) questionnaire; score ranges from 0-54 Month 8
Secondary Anxiety and depression in parents Hospital Anxiety and Depression Scale (HADS) questionnaire; 2 subscores each ranging from 0-21 Baseline
Secondary Anxiety and depression in parents Hospital Anxiety and Depression Scale (HADS) questionnaire; 2 subscores each ranging from 0-21 Month 5
Secondary Anxiety and depression in parents Hospital Anxiety and Depression Scale (HADS) questionnaire; 2 subscores each ranging from 0-21 Month 8
Secondary Self-Esteem and behaviour for children. Rosenberg scale; score ranges from 0-40 Baseline
Secondary Self-Esteem and behaviour for children. Rosenberg scale; score ranges from 0-40 Month 5
Secondary Self-Esteem and behaviour for children. Rosenberg scale; score ranges from 0-40 Month 8
Secondary Self-Esteem and behaviour for children. CONNERS questionnaire for parents; cut-off for significant behavioral problem >15 Baseline
Secondary Self-Esteem and behaviour for children. CONNERS questionnaire for parents; cut-off for significant behavioral problem >15 Month 5
Secondary Self-Esteem and behaviour for children. CONNERS questionnaire for parents; cut-off for significant behavioral problem >15 Month 8
See also
  Status Clinical Trial Phase
Completed NCT03148782 - Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase N/A
Recruiting NCT06038942 - Formal Versus Informal Mindfulness Among University Students With Self-reported ADHD, Nonsuicidal Self-injury, or Stress N/A
Not yet recruiting NCT06456372 - Digital Health Intervention for Children With ADHD N/A
Completed NCT05518435 - Managing Young People With ADHD in Primary Care Study
Active, not recruiting NCT04978792 - Does Cultivating Self-compassion Improve Resilience to Criticism and Improve Mental Health in Adults With ADHD? N/A
Completed NCT03216512 - Effects of Noise Cancelling Headphones on Neurocognitive and Academic Outcomes in ADHD N/A
Completed NCT02829528 - Little Flower Yoga for Kids: Evaluation of a Yoga and Mindfulness Program for Children With Increased Levels of Emotion Dysregulation and Inattention N/A
Not yet recruiting NCT02906501 - Effect of Risperidone on Cognitive Functions in Adolescents With ADHD and Behavioral Disturbances N/A
Completed NCT02900144 - Modified Comprehensive Behavioral Intervention for Tics (M_CBIT) N/A
Completed NCT02562469 - ACTIVATE: A Computerized Training Program for Children With ADHD N/A
Terminated NCT02271880 - Improving Medication Adherence in ADHD Adolescents N/A
Recruiting NCT02255565 - Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study Phase 4
Completed NCT02463396 - Mindfulness Training in Adults With ADHD N/A
Completed NCT01673594 - Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist Phase 4
Terminated NCT01733680 - Amiloride Hydrochloride as an Effective Treatment for ADHD Early Phase 1
Completed NCT02300597 - Internet-based Support for Young People With ADHD and Autism - a Controlled Study N/A
Active, not recruiting NCT01137318 - Combined Cognitive Remediation and Behavioral Intervention for Treatment of Attention-deficit/Hyperactivity Disorder (ADHD) Phase 2
Completed NCT01404273 - Functional MRI of Relaxation Response Training in Adults With Attention-Deficit/Hyperactivity Disorder N/A
Completed NCT00573859 - The Reinforcing Mechanisms of Smoking in Adult ADHD Phase 1/Phase 2
Completed NCT00586157 - Study of Medication Patch to Treat Children Ages 6-12 With ADHD Phase 4